FirsthandHealth
FDA MedWatch Safety AlertsUnited States20 November 2026

FDA issues alert on Heraeus Medevio recall of vascular guidewires over coating defects

On November 20, 2026, the US Food and Drug Administration issued an early alert regarding a voluntary recall of certain vascular guidewires by Heraeus Medical Components, also known as Heraeus Medevio. The company sent letters to customers on November 4 and 5, 2026, advising them to stop using and distributing specific lots of Navilyst, Spectrum, and Arrow Marked guidewires. The problem involves the hydrophilic coating on the guidewires, which can swell unevenly when exposed to saline and clump together, particularly on the distal coil section. This clumping raises the risk that pieces of the coating could flake off or detach into a patient's bloodstream, potentially causing blockages or other severe medical complications. As of November 5, 2026, Heraeus Medevio had not reported any serious injuries or deaths related to the issue. Healthcare facilities are instructed to check inventory, quarantine affected products, and contact the manufacturer or report problems through the FDA MedWatch system.

What was announced

The US Food and Drug Administration published an early alert on November 20, 2026, regarding a voluntary medical device recall initiated by Heraeus Medical Components. On November 4 and 5, 2026, Heraeus Medevio sent a letter recommending that customers immediately quarantine and stop using or distributing certain vascular guidewires.

The affected products include specific lots of Navilyst Vascular Guidewire, Spectrum Vascular Guidewire, and Arrow Marked Guidewire. These tools consist of a nickel titanium alloy with a metallic coil tip and are used for percutaneous entry into peripheral blood vessels. Heraeus Medevio identified a potential quality flaw where the hydrophilic coating on the wire swells unevenly when hydrated with saline. This uneven swelling causes the coating to clump, mostly on the wire's coil section near the tip.

What it means

When the coating clumps, pieces of the hydrophilic polymer can flake off, shift, or detach. If these fragments enter a patient's bloodstream, they can travel through blood vessels and block circulation. This condition is known as hydrophilic polymer embolization.

Depending on where the particles travel, blockages can affect critical organs like the heart, brain, lungs, or kidneys. Documented complications from polymer embolization include vascular blockages, tissue death, bleeding, strokes, organ failure, and death. In venous procedures, detached particles generally reach the lungs. For patients with specific heart conditions, such as a right-to-left shunt, particles can enter systemic blood circulation. As of November 5, 2026, the company reported no serious injuries or deaths connected to this recall.

What the announcement does not tell us

The FDA alert does not state the exact number of guidewires or lots impacted by this recall. It also does not explain what caused the manufacturing failure in the hydrophilic coating or when the defect was first discovered. Additionally, the notice does not detail how many medical facilities received the affected products or how long the FDA review will take before issuing a final status update.

How this was written

This analysis was written with AI from the official announcement below, using only facts that announcement states. The quoted wording is FDA MedWatch Safety Alerts’s own. Always check the original before acting on anything here.

Vascular guidewire coating may displace or detach and enter patient bloodstream.
Source: FDA MedWatch Safety Alerts

More from FDA MedWatch Safety Alerts

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.